Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
VTR-297 by Vanda Pharmaceuticals for Onychomycosis (Tinea Unguium): Likelihood of Approval
VTR-297 is under clinical development by Vanda Pharmaceuticals and currently in Phase I for Onychomycosis (Tinea Unguium). According to GlobalData,...
VTR-297 by Vanda Pharmaceuticals for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma): Likelihood of Approval
VTR-297 is under clinical development by Vanda Pharmaceuticals and currently in Phase II for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma). According...
VTR-297 by Vanda Pharmaceuticals for Non-Hodgkin Lymphoma: Likelihood of Approval
VTR-297 is under clinical development by Vanda Pharmaceuticals and currently in Phase II for Non-Hodgkin Lymphoma. According to GlobalData, Phase...
VTR-297 by Vanda Pharmaceuticals for Multiple Myeloma (Kahler Disease): Likelihood of Approval
VTR-297 is under clinical development by Vanda Pharmaceuticals and currently in Phase II for Multiple Myeloma (Kahler Disease). According to...